Answer
Women of childbearing potential should continue effective contraception for at least 4 months after their last dose of pembrolizumab.
Sources for this answer
- KEYTRUDA 25 mg/mL concentrate for solution for infusionMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 64Document updated
Sources checked